Translations:ENDS Toxicity / Carcinogenic/16/en
Jump to navigation Jump to search
- In this study, we have demonstrated that no clinically relevant, product-related safety findings were observed for smokers of Combustible Cigarettes (CC) switching to an Electronic Vapor Product (EVP) for 12 weeks under real-life settings. Adverse Effects (AEs) reported by subjects switching to the EVP occurred primarily within the first week after switching, and only 1.3% of all AEs reported were considered to be almost definitely related to the product. Up to a third of all reported AEs in the EVP group were related to nicotine withdrawal symptoms, which were observed to decrease after the first two weeks from product switch. EVP use was associated with significant decreases in exposure to nicotine and other chemicals such as benzene and acrolein, typically found in CC smoke. Changes were also observed in the level of WBC, haemoglobin, RBC and LDL cholesterol, which although minor, were consistent with those observed after smoking cessation. The data presented in this study shows the potential that EVPs may offer to smokers looking for an alternative to CCs.
- PDF Version
- Citation: Mauro Scungio, Luca Stabile, Giorgio Buonanno, Measurements of electronic cigarette-generated particles for the evaluation of lung cancer risk of active and passive users, Journal of Aerosol Science, Volume 115, 2018, Pages 1-11, ISSN 0021-8502, doi:10.1016/j.jaerosci.2017.10.006.
- Keywords: E-cigs: Electronic cigarettesUltrafine particlesELCRLung cancer risk